Aptus Capital Advisors LLC Buys 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aptus Capital Advisors LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 974 shares of the biopharmaceutical company’s stock after purchasing an additional 32 shares during the period. Aptus Capital Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,024,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in REGN. Aigen Investment Management LP bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $760,000. Prime Capital Investment Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 1.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 1,298 shares of the biopharmaceutical company’s stock worth $1,365,000 after purchasing an additional 19 shares in the last quarter. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock valued at $316,957,000 after buying an additional 3,866 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd grew its position in shares of Regeneron Pharmaceuticals by 286.8% in the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,319 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 978 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,097.14.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $782.51 on Friday. The company has a market cap of $85.99 billion, a P/E ratio of 19.36, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $780.95 and a 1 year high of $1,211.20. The stock’s fifty day moving average price is $1,000.06 and its 200-day moving average price is $1,035.67.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.